Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Lichao Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4133-6590; OpenAlex author ID A5103175172. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
5
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 3

  1. OIP5-AS1 enhances the malignant characteristics and resistance to chemotherapy of pancreatic cancer cells by targeting miR-30d-5p/MARCH8. Co-author DOI 10.1016/j.heliyon.2024.e33835↗
  2. E3 Ubiquitin Ligase MARCH8 Promotes Pancreatic Cancer Growth and Metastasis by Activating STAT3 via Degradation of PTPN4. Co-author DOI 10.1097/mpa.0000000000002244↗
  3. Survival-Associated Alternative Splicing Events and Prognostic Signatures in Pancreatic Cancer. Co-author DOI 10.3389/fgene.2020.522383↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xinhong He · 2 shared papers, 2023–2024 · strength 0.38
  2. Leilei Ying · 1 shared paper, 2024 · strength 0.20
  3. Wentao Li · 1 shared paper, 2024 · strength 0.20
  4. Chao Chen · 1 shared paper, 2023 · strength 0.18
  5. Hongda Pan · 1 shared paper, 2020 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.